购物车
您的购物车当前为空
RO7567132(FAP-LTBR)是一种新型双特异性抗体,双价结合并激动LTBR,单价结合并拮抗FAP,从而将LTBR的活化局限于肿瘤微环境,诱导局部三级淋巴结构(TLS)形成,减少系统性毒性。其鼠源替代物可抑制乳腺癌生长,联合阿特珠单抗效果更佳。在小鼠结直肠癌模型中,也可增强免疫细胞浸润与TLS样结构形成。
别名 RO 7567132, RG6221, RG 6221, FAP-LTBR, FAPLTBR
RO7567132(FAP-LTBR)是一种新型双特异性抗体,双价结合并激动LTBR,单价结合并拮抗FAP,从而将LTBR的活化局限于肿瘤微环境,诱导局部三级淋巴结构(TLS)形成,减少系统性毒性。其鼠源替代物可抑制乳腺癌生长,联合阿特珠单抗效果更佳。在小鼠结直肠癌模型中,也可增强免疫细胞浸润与TLS样结构形成。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | 待询 | 待询 | |
| 5 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation. |
| 别名 | RO 7567132, RG6221, RG 6221, FAP-LTBR, FAPLTBR |
| 反应种属 | Human |
| 应用 | ELISAFACSFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 偶联 | Unconjugated |
| 靶点 | FAP/TNFRSF3 |
| 存储 | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多